Skip to main content

REVIEW article

Front. Endocrinol.
Sec. Obesity
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1456948
This article is part of the Research Topic Lipid Metabolism Dysregulation in Obesity-Related Diseases and Neurodegeneration View all 6 articles

Therapeutic targeting of obesity-induced neuroinflammation and neurodegeneration

Provisionally accepted
  • Nanyang Technological University, Singapore, Singapore

The final, formatted version of the article will be published soon.

    Obesity is a major modifiable risk factor leading to neuroinflammation and neurodegeneration. Excessive fat storage in obesity promotes the progressive infiltration of immune cells into adipose tissue, resulting in the release of pro-inflammatory factors such as cytokines and adipokines. These inflammatory mediators circulate through the bloodstream, propagating inflammation both in the periphery and in the central nervous system. Gut dysbiosis, which results in a leaky intestinal barrier, exacerbates inflammation and plays a significant role in linking obesity to the pathogenesis of neuroinflammation and neurodegeneration through the gut-brain/gut-brain-liver axis. Inflammatory states within the brain can lead to insulin resistance, mitochondrial dysfunction, autolysosomal dysfunction, and increased oxidative stress. These disruptions impair normal neuronal function and subsequently lead to cognitive decline and motor deficits, similar to the pathologies observed in major neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease. Understanding the underlying disease mechanisms is crucial for developing therapeutic strategies to address defects in these inflammatory and metabolic pathways. In this review, we summarize and provide insights into different therapeutic strategies, including methods to alter gut dysbiosis, lifestyle changes, dietary supplementation, as well as pharmacological agents derived from natural sources, that target obesity-induced neuroinflammation and neurodegeneration.

    Keywords: Obesity, metabolic dysfunciton, Neuroinflammation, neurodegeneration, Body-brain interactions, Therapeutic targeting

    Received: 29 Jun 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Zeng, Tong Cheong and Lo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jialiu Zeng, Nanyang Technological University, Singapore, Singapore
    Chih Hung Lo, Nanyang Technological University, Singapore, Singapore

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.